Ahmed A Othman Selected Research

Benztropine (Benzatropine)

12/2008	The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse.
5/2008	Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse.
1/2007	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ahmed A Othman Research Topics

Disease

30	Rheumatoid Arthritis 01/2022 - 12/2016
12	Infections 11/2020 - 12/2016
10	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 11/2018
8	Body Weight (Weight, Body) 01/2020 - 09/2011
7	Schizophrenia (Dementia Praecox) 05/2018 - 04/2011
6	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 01/2019
6	Herpes Zoster 11/2020 - 01/2018
6	Crohn Disease (Crohn's Disease) 01/2020 - 12/2016
6	Multiple Sclerosis 11/2016 - 10/2014
5	Psoriatic Arthritis 01/2019 - 01/2018
5	Parkinson Disease (Parkinson's Disease) 01/2017 - 04/2013
4	Cognitive Dysfunction 05/2018 - 11/2014
3	Atopic Dermatitis (Atopic Eczema) 01/2021 - 01/2020
3	Pain (Aches) 11/2019 - 07/2012
3	Neoplasms (Cancer) 11/2019 - 01/2018
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 04/2011
3	Hypersensitivity (Allergy) 11/2018 - 12/2017
3	Dementia (Dementias) 10/2016 - 01/2014
3	Cocaine-Related Disorders (Cocaine Addiction) 12/2008 - 01/2007
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2018
2	Inflammation (Inflammations) 01/2021 - 12/2017
2	Ulcerative Colitis 01/2020 - 01/2020
2	Pulmonary Embolism 01/2020 - 01/2019
2	Pneumonia (Pneumonitis) 01/2020 - 12/2016
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 01/2018
2	Constipation 05/2018 - 01/2016
2	Headache (Headaches) 01/2018 - 01/2016
2	Diarrhea 08/2016 - 01/2016
2	Relapsing-Remitting Multiple Sclerosis 01/2016 - 01/2016
2	Bronchopulmonary Dysplasia 05/2013 - 09/2011
2	Substance-Related Disorders (Drug Abuse) 08/2007 - 01/2007
1	Breast Neoplasms (Breast Cancer) 11/2021
1	Eczema 01/2021
1	Opportunistic Infections (Opportunistic Infection) 11/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2020
1	Ruptured Aneurysm 01/2019
1	Stroke (Strokes) 01/2019

Drug/Important Bio-Agent (IBA)

27	upadacitinibIBA 01/2022 - 12/2016
11	Janus Kinase 1IBA 01/2021 - 01/2018
10	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 12/2016
9	risankizumabIBA 01/2020 - 10/2018
9	Monoclonal AntibodiesIBA 01/2020 - 10/2014
8	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 05/2018 - 04/2011
7	Interleukin-17 (Interleukin 17)IBA 01/2019 - 12/2017
6	ABT-122IBA 01/2019 - 12/2017
6	ABT-126IBA 05/2018 - 06/2015
5	Cytochrome P-450 CYP3AIBA 11/2021 - 01/2016
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 12/2016
5	Levodopa (L Dopa)FDA LinkGeneric 01/2017 - 04/2013
5	Carbidopa (Lodosyn)FDA LinkGeneric 01/2017 - 04/2013
5	Interleukin-2 Receptors (IL 2 Receptor)IBA 11/2016 - 10/2014
5	daclizumab HYPIBA 11/2016 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2016
4	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2021 - 01/2016
4	Midazolam (Versed)FDA LinkGeneric 01/2021 - 01/2016
4	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 01/2021 - 01/2016
4	Cytochrome P-450 CYP2C9IBA 01/2021 - 01/2016
4	Interleukin-23 (Interleukin 23)IBA 01/2020 - 10/2018
4	Janus KinasesIBA 01/2020 - 01/2018
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
3	Caffeine (No Doz)FDA LinkGeneric 01/2021 - 01/2016
3	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 01/2016
3	EnzymesIBA 01/2021 - 01/2016
3	Cytochrome P-450 CYP2C19IBA 01/2020 - 01/2016
3	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2020 - 01/2016
3	Delayed-Action PreparationsIBA 01/2020 - 01/2019
3	Antipsychotic Agents (Antipsychotics)IBA 05/2018 - 06/2014
3	2- (4'- (5- methylhexahydropyrrolo(3,4- b)pyrrol- 1- yl)biphenyl- 4- yl)- 2H- pyridazin- 3- oneIBA 11/2014 - 01/2014
3	ABT 102IBA 02/2013 - 01/2012
3	Benztropine (Benzatropine)FDA LinkGeneric 12/2008 - 01/2007
2	GLPG0634IBA 01/2022 - 01/2022
2	venetoclaxIBA 01/2020 - 01/2018
2	CreatinineIBA 01/2020 - 01/2020
2	C-Reactive ProteinIBA 01/2020 - 11/2018
2	Adalimumab (Humira)FDA Link 01/2020 - 11/2019
2	Hemoglobins (Hemoglobin)IBA 01/2020 - 01/2020
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 01/2016
2	Creatine Kinase (Creatine Phosphokinase)IBA 11/2019 - 06/2014
2	Omeprazole (Prilosec)FDA LinkGeneric 01/2019 - 01/2016
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 01/2018
2	TabletsIBA 09/2015 - 07/2014
2	Azithromycin (Zithromax)FDA LinkGeneric 05/2013 - 09/2011
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	LipidsIBA 01/2022
1	tirabrutinibIBA 01/2022
1	AnionsIBA 11/2021
1	Atorvastatin (Lipitor)FDA Link 11/2021
1	Peptides (Polypeptides)IBA 11/2021
1	Rosuvastatin Calcium (Crestor)FDA Link 11/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Serum AlbuminIBA 01/2020
1	tofacitinibIBA 01/2020
1	AntibodiesIBA 01/2020
1	InterleukinsIBA 10/2019
1	AlbuminsIBA 01/2019
1	alicapistatIBA 01/2019

Therapy/Procedure

10	Therapeutics 01/2020 - 01/2007
2	Oral Administration 09/2015 - 07/2014
1	Aftercare (After-Treatment) 01/2020